Advanced search
Publication Cover
Drug Design, Development and Therapy Volume 14, 2020 - Issue
Submit an article Journal homepage
141
Views
11
CrossRef citations to date
0
Altmetric
Review

Characteristics of COVID-19 Clinical Trials in China Based on the Registration Data on ChiCTR and ClinicalTrials.gov

Jihan Huang1 Center for Drug Clinical Research, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, People’s Republic of ChinaCorrespondence[email protected] [email protected]
ORCID Iconhttps://orcid.org/0000-0002-2176-737X
ORCID Icon,
Yingchun He1 Center for Drug Clinical Research, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, People’s Republic of China
,
Qianmin Su2 Department of Computer in College of Electronic and Electrical Engineering, Shanghai University of Engineering Science, Shanghai 201620, People’s Republic of China
&
Juan Yang1 Center for Drug Clinical Research, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0001-7429-6164
ORCID Icon
Pages 2159-2164 | Published online: 29 May 2020

References

  • MengL, HuaF, BianZ. Coronavirus disease 2019 (COVID-19): emerging and future challenges for dental and oral medicine. J Dent Res. 2020;99(5):481–487. doi:10.1177/002203452091424632162995
  • GuanWJ, NiZY, HuY, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708–1720. doi:10.1056/NEJMoa200203232109013
  • WuF, ZhaoS, YuB, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579:265–269. doi:10.1038/s41586-020-2008-332015508
  • ZhuN, ZhangD, WangW, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–733. doi:10.1056/NEJMoa200101731978945
  • VellingiriB, JayaramayyaK, IyerM, et al. COVID-19: a promising cure for the global panic. Sci Total Environ. 2020;725:138277. doi:10.1016/j.scitotenv.2020.13827732278175
  • LuH. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends. 2020;14:69–71. doi:10.5582/bst.2020.0102031996494
  • IyerM, JayaramayyaK, SubramaniamMD, et al. COVID-19: an update on diagnostic and therapeutic approaches. BMB Rep. 2020;53(4):191–205. doi:10.5483/BMBRep.2020.53.4.08032336317
  • McCrayAT. Better access to information about clinical trials. Ann Intern Med. 2000;133(8):609–614. doi:10.7326/0003-4819-133-8-200010170-0001311033590
  • ZarinDA, TseT. Medicine. Moving toward transparency of clinical trials. Science (New York, NY). 2008;319(5868):1340–1342. doi:10.1126/science.1153632
  • TseT, WilliamsRJ, ZarinDA. Reporting “basic results” in ClinicalTrials.gov. Chest. 2009;136(1):295–303. doi:10.1378/chest.08-302219584212
  • ZarinDA, IdeNC, TseT, HarlanWR, WestJC, LindbergDA. Issues in the registration of clinical trials. JAMA. 2007;297(19):2112–2120. doi:10.1001/jama.297.19.211217507347
  • ZarinDA, KeselmanA. Registering a clinical trial in ClinicalTrials.gov. Chest. 2007;131(3):909–912. doi:10.1378/chest.06-245017303677
  • HuangJH, SuQM, YangJ, et al. Sample sizes in dosage investigational clinical trials: a systematic evaluation. Drug Des Devel Ther. 2015;9:305–312. doi:10.2147/DDDT.S76135
  • HeY, YangJ, LvY, et al. A review of ginseng clinical trials registered in the WHO international clinical trials registry platform. Biomed Res Int. 2018;2018:1843142. doi:10.1155/2018/184314229546050
  • ChenJ, HuangJ, LiJV, LvY, HeY, ZhengQ. The characteristics of TCM clinical trials: a systematic review of clinicalTrials.gov. Evid Based Complement Alternat Med. 2017;2017:9461415. doi:10.1155/2017/946141529138646
  • ZhangQ, WangY, QiC, ShenL, LiJ. Clinical trial analysis of 2019-nCoV therapy registered in China. J Med Virol. 2020;92:540–545. doi:10.1002/jmv.25733
  • MadP, Felder-PuigR, GartlehnerG. [Randomised controlled trials]. Wien Med Wochenschr. 2008;158(7–8):234–239. German. doi:10.1007/s10354-008-0526-y18500478
  • GraylingMJ, ManderAP. Do single-arm trials have a role in drug development plans incorporating randomised trials? Pharm Stat. 2016;15(2):143–151. doi:10.1002/pst.172626609689
  • DongL, HuS, GaoJ. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. 2020;14(1):58–60. doi:10.5582/ddt.2020.0101232147628
  • ShirakiK, DaikokuT. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacol Ther. 2020;209:107512. doi:10.1016/j.pharmthera.2020.10751232097670
  • Muyembe-TamfumJJ, SivaheraB, CamaraM, et al. A randomized, controlled trial of ebola virus disease therapeutics. N Engl J Med. 2019;381(24):2293–2303. doi:10.1056/NEJMoa191099331774950
  • HolshueML, DeBoltC, LindquistS, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020;382(10):929–936. doi:10.1056/NEJMoa200119132004427
  • WangY, ZhangD, DuG, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395:1569–1578. doi:10.1016/s0140-6736(20)31022-932423584
  • ColsonP, RolainJM, LagierJC, BrouquiP, RaoultD. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents. 2020;55:105932. doi:10.1016/j.ijantimicag.2020.10593232145363
  • GautretP, LagierJC, ParolaP. et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents;2020 105949. doi:10.1016/j.ijantimicag.2020.10594932205204

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.